AI Research, page-20

OncoSil Medical: Top 10 Q&A

Q1: Is GBA approval still a good thing?
A: Yes, absolutely. GBA approval is a major milestone, reinforcing OncoSil’s credibility and growth potential in the medical field.

Q2: Is OncoSil still a good stock? Have the fundamentals changed for the worse?
A: No, the fundamentals have actually improved, positioning OncoSil even stronger in the market.

Q3: Are funds supporting us?
A: Yes, recent announcements show solid backing from institutional funds.

Q4: Is the management team good?
A: Yes, they are very experienced and continue to drive the company in the right direction.

Q5: Was the capital raise (CR) a disaster?
A: No, it wasn’t a disaster; the outcome was just different from what many anticipated.

Q6: Are the future prospects good or bad?
A: The future prospects look promising, especially after the recent distribution team meeting in Vienna, signalling efforts to expand market presence.

Q7: Should we expect news on MDR approval soon?
A: Yes, MDR approval is expected in the near future, as mentioned in recent company updates.

Q8: Is CEO Lange highly experienced?
A: Yes, CEO Nigel Lange has over 35 years of experience in medical devices and pharmaceuticals, with extensive expertise in brachytherapy.

Q9: Will BlackRock or Vanguard take notice of OncoSil, or are we too small?
A: Currently, OncoSil may be below their typical investment threshold, but consistent growth and stronger financials could attract their interest in the future.

Q10: Is the future bright or doomed?
A: The future is bright, highlighted by two recent achievements: a 78% increase in device usage by June 2024 and positive comparative analysis results in September 2024 showing significant survival and disease control benefits with OncoSil™ when adding to chemotherapy.

These developments underscore OncoSil's progress, solidifying its potential for continued success in the industry.